Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosiglitazone XR in Alzheimer's Disease (REFLECT-2)
NCT00348309Phase 3Completed
- Sponsor
- GSK
- Start
- Jul 2006
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 3 trial of rosiglitazone in Alzheimer's disease (AD), sponsored by GSK. Started Jul 2006; status: completed.
02
Drugs
rosiglitazone
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00348309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00348309.